טוען...
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
SIMPLE SUMMARY: Despite the emergence of new therapies during the last decade, metastatic castration-resistant prostate cancer (mCRPC) remains fatal. Recent work showed that the timing of treatment initiation seems critical for patient outcomes. Thus, it is key to identify factors that can help in d...
שמור ב:
| הוצא לאור ב: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8002173/ https://ncbi.nlm.nih.gov/pubmed/33805793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061284 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|